Rheumatoid Arthritis | Access and Reimbursement | US | 2016

Publish date: August 2016

Login to access report

The U.S. rheumatoid arthritis (RA) market is crowded, with the availability of nine different biologics and Xeljanz, representing six distinct drug classes. With the impending entry of biosimilars and emerging therapies (Jak and IL-6 inhibitors), marketers will be faced with increased challenges to gain favorable formulary positioning and physician uptake. Rheumatoid Arthritis | Access & Reimbursement | US examines the prescribing and reimbursement environment for current and emerging RA agents, according to surveyed rheumatologists and managed care organization (MCO) pharmacy directors and medical directors. This content explores stakeholder perspectives that affect prescribing and reimbursement of key RA agents and dynamics that will promote or restrict market access and uptake of emerging RA therapies.